Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice

Microbiology and Immunology

Volumn 53, Issue 11, 2009, Pages 587-594

  Moriyama, Kiyoshi ^a,d   Wiener Kronish, Jeanine P ^a,b,c   Sawa, Teiji ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KYOTO FIRST RED CROSS HOSPITAL   (Japan)

Author keywords

Affinity purified antibody; Component vaccine; Pseudomonas aeruginosa PcrV

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; CYCLOPHOSPHAMIDE; EPITOPE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 166; PROTEIN PCRV[1-294]; PROTEIN PCRV[139-234]; PROTEIN PCRV[139-258]; PROTEIN PCRV[139-294]; PROTEIN PCRV[197-294]; PROTEIN PCRV[261-294]; PSEUDOMONAS AERUGINOSA V ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GENETIC ENGINEERING; HUMAN; IMMUNE DEFICIENCY; LETHALITY; MALE; MOUSE; NEUTROPENIA; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SURVIVAL; TYPE III SECRETION SYSTEM;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CYCLOPHOSPHAMIDE; IMMUNIZATION, PASSIVE; IMMUNOSUPPRESSION; MALE; MICE; MICE, INBRED BALB C; NEUTROPENIA; PORE FORMING CYTOTOXIC PROTEINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES; VACCINES, SYNTHETIC;

MUS; PSEUDOMONAS AERUGINOSA;

EID: 75749100252     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2009.00165.x     Document Type: Article

References (30)

1. National Nosocomial Infection Surveillance System. (2004) National Nosocomial Infection Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32: 470-85.
2. Brun-Buisson C., Doyon F., Carlet J., Dellamonica P., Gouin F., Lepoutre A., et al. (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 274: 968-74.
3. Vidal F., Mensa J., Almela M., Martinez J.A., Marco F., Casals C., et al. (1996) Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 156: 2121-6.
4. Casadevall A. (1996) Antibody-based therapies for emerging infectious diseases. Emerging Infect Dis 2: 200-8.
5. Holder I.A. (2001) Pseudomonas vaccination and immunotherapy: an overview. J Burn Care Rehabil 22: 311-20.
6. El Solh A.A., Akinnusi M.E.,Wiener-Kronish J.P., Lynch S.V., Pineda L.A., Szarpa K. (2008) Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 178: 513-9.
7. Sawa T., Yahr T.L., Ohara M., Kurahashi K., Gropper M.A., Wiener-Kronish J.P., et al. (1999) Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 5: 392-8.
8. Shime N., Sawa T., Fujimoto J., Faure K., Allmond L.R., Karaca T., et al. (2001) Therapeutic administration of anti-PcrV F(ab')2 in sepsis associated with Pseudomonas aeruginosa. J Immunol 167: 5880-6.
9. Holder I.A., Neely A.N., Frank D.W. (2001) PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect Immun 69: 5908-10.
10. Frank D.W., Vallis A.,Wiener-Kronish J.P., Roy-Burman A., Spack E.G., Mullaney B.P., et al. (2002) Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 186: 64-73.
11. Faure K., Fujimoto J., Shimabukuro D.W., Ajayi T., Shime N., Moriyama K., et al. (2003) Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a ratmodel. J Immune Based Therapy and Vaccine 1: 2.
12. Yahr T.L., Mende-Mueller L.M., Friese M.B., Frank D.W. (1997) Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon. J Bacteriol 179: 7165-8.
13. Burrows T.W. (1956) An antigen determining virulence in Pasteurella pestis. Nature (London) 177: 426-7.
14. Burrows T.W., Bacon G.A. (1958) The effects of loss of virulence determinants on the virulence and immunogenicity of strains of Pasteurella pestis. Brit J Exp Pathol 39: 278-91.
15. Une T., Brubaker R.R. (1984) Roles of V antigen in promoting virulence and immunity in Yersiniae. J Immunol 133: 2226-30.
16. Motin V.L., Nakajima R., Smirnov G.B., Brubaker R.R. (1994) Passive immunity to Yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun 62: 4192-201.
17. Leary S.E.C.,Wiiliamson E.D., Griffin K.F., Russell P., Eley S.M., Titball R.W. (1995) Active immunization with recombinant V antigen from Yersinia pesitis protects mice against plague. Infect Immun 63: 2854-8.
18. Anderson G.W., Leary S.E.C.,Williamson E.D., Titball R.W.,Welkos S.L.,Worsham P.L., et al. (1996) Recombinant V antigen protects mice against pneumonic and bubonic plague against F1 capsule positive and negative strains of Y. pestis. Infect Immun 64: 4580-5.
19. Sato K., Nakajima R., Hara F., Une T., Osada Y. (1991) Preparation of monoclonal antibody to V antigen from Yersinia pestis. Contrib Microbiol Immunol 12: 225-9.
20. Pettersson J., Holmstrom A., Hill J., Leary S., Frithz-Lindsten E., von Euler-Matell A., et al. (1999) The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol Microbiol 32: 961-76.
21. Imamura Y., Yanagihara K., Fukuda Y., Kaneko Y., Seki M., Izumikawa K., et al. (2007) Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur Respir J. 29: 965-8.
22. Sawa T., Ohara M., Kurahashi K., Twining S.S., Frank D.W., Doroques D.B., et al. (1998) In vitro cellular toxicity predicts Pseudomonas aeruginosa virulence in lung infections. Infect Immun 66: 3242-9.
23. Oishi K., Sonoda F., Iwagaki A., Kobayashi S., Nagatake T., Matsumoto K. (1992) Effects of the combination of lipopolysaccharide-specific monoclonal antibodies and sparfloxacin against Pseudomonas aeruginosa pneumonia in neutropenic mice. Antimicrob Agents Chemother 36: 1352-7.
24. Oishi K., Sonoda F., Iwagaki A., Ponglertnapagorn P.,Watanabe K., Nagatake T., et al. (1993) Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother 37: 164-70.
25. Yahr T.L., Vallis A.J., Hancock M.K., Barbieri J.T., Frank D.W. (1998) ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc Natl Acad Sci USA 95: 13899-904.
26. Stover C.K., Pham X.Q., Erwin A.L., Mizoguchi S.D.,Warrener P., Hickey M.J., et al. (2000) Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406: 959-64.
27. Sing A., Rost D., Tvardovskaia N., Roggenkamp A.,Wiedemann A., Kirshning C.J., et al. (2002) Yersinia V-antigen exploits Toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J ExpMed 196: 1017-24.
28. Sing A., Roggenkamp A., Geiger A.M., Heesemann J. (2002) Yersinia enterocolitica evasion of the host innate immune response by V antigen-induced IL-10 production of macrophages is abrogated in IL-10-deficient mice. J Immunol 168: 1315-21.
29. Nakajima R., Brubaker R.R. (1993) Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor-α. Infect Immun 61: 23-31.
30. Roggenkamp A., Geiger A.M., Leitritz L., Kessler A., Heesemann J. (1997) Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect Immun 65: 446-51.